X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. ((1r,2r,3as,9as)-2-hydroxy-1-((3s)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1h-cylopent(b)naphthalen-5-yl)oxy)acetate
2. Orenitram
3. Remodulin
4. Trepostinil Sodium
5. Treprostinil Diethanolamine
6. Treprostinil Diolamin
7. Treprostinil Diolamine
8. Treprostinil Sodium
9. Ut-15
10. Ut-15c
1. 81846-19-7
2. Remodulin
3. Uniprost
4. Rumodolin
5. Orenitram
6. Tyvaso
7. Lrx-15
8. Ut-15
9. 15au81
10. Treprostinil Free Acid
11. Rum6k67esg
12. 2-(((1r,2r,3as,9as)-2-hydroxy-1-((s)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[b]naphthalen-5-yl)oxy)acetic Acid
13. Chebi:50861
14. 81846-19-7 (free Acid)
15. ((1r,2r,3as,9as)-2-hydroxy-1-((3s)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1h-cylopent(b)naphthalen-5-yl)oxy)acetate
16. 2-[[(1r,2r,3as,9as)-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[g]naphthalen-5-yl]oxy]acetic Acid
17. 289480-64-4
18. 15-au-81
19. L-606
20. Treprostinilo
21. Treprostinilum
22. Lrx 15
23. Treprostinil [usan:inn]
24. Remodulin (tn)
25. Unii-rum6k67esg
26. U 62840
27. Tresprostinil
28. Trevyent
29. U-62,840
30. Treprostinil [mi]
31. Treprostinil [inn]
32. Treprostinil [jan]
33. Treprostinil [usan]
34. Treprostinil [vandf]
35. Treprostinil Pound>>ut-15
36. Treprostinil [mart.]
37. Treprostinil [who-dd]
38. 15au
39. Gtpl5820
40. Schembl4349618
41. Treprostinil (jan/usan/inn)
42. Chembl1237119
43. Lrx -15
44. Dtxsid901021654
45. Hms3648g07
46. Treprostinil [orange Book]
47. Amy22230
48. Bcp10253
49. Ex-a1414
50. Zinc3800475
51. Mfcd00888847
52. Akos027470173
53. Cs-7872
54. Db00374
55. Ncgc00343944-03
56. ({(1r,2r,3as,9as)-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[b]naphthalen-5-yl}oxy)acetic Acid
57. 2-[[(1r,2r,3as,9as)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-1h-benz[f]inden-5-yl]oxy]acetic Acid
58. Ac-30207
59. As-56364
60. L606
61. Hy-100441
62. D06213
63. Sr-01000946210
64. Q3495231
65. Sr-01000946210-1
66. Brd-k19706299-001-01-4
67. [[(1r,2r,3as,9as)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(s)-3-hydroxyoctyl]-1h-benzo[f]indene-5-yl]oxy]acetic Acid
68. [[(1r,2r,3as,9as)-2,3,4,9,9a-hexahydro-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-1h-benz[f]inden-5-yl]oxy]acetic Acid
69. 2-((1r,2r,3as,9as)-2-hydroxy-1-((s)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[b]naphthalen-5-yloxy)acetic Acid
70. 2-[[(1r,2r,3as,9as)-2,3,4,9,9a-hexahydro-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-1h-benz[f]inden-5-yl]oxy]-acetic Acid
71. 2-[[(2r,3r,3as,9as)-2-hydroxy-3-[(3s)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[g]naphthalen-8-yl]oxy]acetic Acid
72. 2-{[(1r,2r,3as,9as)-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-1h,2h,3h,3ah,4h,9h,9ah-cyclopenta[b]naphthalen-5-yl]oxy}acetic Acid
73. Acetic Acid, (((1r,2r,3as,9as)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3s)-3-hydroxyoctyl)-1h-benz(f)inden-5-yl)oxy)-
74. Acetic Acid, ((2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-(3-hydroxyoctyl)-1h-benz(f)inden-5-yl)oxy)-, (1r-(1alpha(s*),2beta,3aalpha,9aalpha))-
75. Acetic Acid,(((1r,2r,3as,9as)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3s)-3-hydroxyoctyl)-1h-benz(f)inden-5-yl)oxy)-
| Molecular Weight | 390.5 g/mol |
|---|---|
| Molecular Formula | C23H34O5 |
| XLogP3 | 4.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 10 |
| Exact Mass | 390.24062418 g/mol |
| Monoisotopic Mass | 390.24062418 g/mol |
| Topological Polar Surface Area | 87 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 495 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Remodulin |
| PubMed Health | Treprostinil |
| Drug Classes | Antihypertensive, Cardiovascular Agent, Platelet Aggregation Inhibitor, Vasodilator |
| Drug Label | Remodulin (treprostinil) Injection is a sterile solution of treprostinil formulated for subcutaneous or intravenous administration. Remodulin is supplied in 20 mL multidose vials in four strengths, containing 20 mg, 50 mg, 100 mg, or 200 mg (1 mg/mL,... |
| Active Ingredient | Treprostinil |
| Dosage Form | Injectable |
| Route | Iv (infusion), subcutaneous |
| Strength | 1mg/ml; 2.5mg/ml; 10mg/ml; 5mg/ml |
| Market Status | Prescription |
| Company | United Therap |
| 2 of 4 | |
|---|---|
| Drug Name | Tyvaso |
| PubMed Health | Treprostinil (By breathing) |
| Drug Classes | Vasodilator |
| Drug Label | Tyvaso is a sterile formulation of treprostinil intended for administration by oral inhalation using the Tyvaso Inhalation System. Tyvaso is supplied in 2.9 mL low density polyethylene (LDPE) ampules, containing 1.74 mg treprostinil (0.6 mg/mL). Each... |
| Active Ingredient | Treprostinil |
| Dosage Form | Solution |
| Route | Inhalation |
| Strength | eq 0.6mg base/ml |
| Market Status | Prescription |
| Company | United Therap |
| 3 of 4 | |
|---|---|
| Drug Name | Remodulin |
| PubMed Health | Treprostinil |
| Drug Classes | Antihypertensive, Cardiovascular Agent, Platelet Aggregation Inhibitor, Vasodilator |
| Drug Label | Remodulin (treprostinil) Injection is a sterile solution of treprostinil formulated for subcutaneous or intravenous administration. Remodulin is supplied in 20 mL multidose vials in four strengths, containing 20 mg, 50 mg, 100 mg, or 200 mg (1 mg/mL,... |
| Active Ingredient | Treprostinil |
| Dosage Form | Injectable |
| Route | Iv (infusion), subcutaneous |
| Strength | 1mg/ml; 2.5mg/ml; 10mg/ml; 5mg/ml |
| Market Status | Prescription |
| Company | United Therap |
| 4 of 4 | |
|---|---|
| Drug Name | Tyvaso |
| PubMed Health | Treprostinil (By breathing) |
| Drug Classes | Vasodilator |
| Drug Label | Tyvaso is a sterile formulation of treprostinil intended for administration by oral inhalation using the Tyvaso Inhalation System. Tyvaso is supplied in 2.9 mL low density polyethylene (LDPE) ampules, containing 1.74 mg treprostinil (0.6 mg/mL). Each... |
| Active Ingredient | Treprostinil |
| Dosage Form | Solution |
| Route | Inhalation |
| Strength | eq 0.6mg base/ml |
| Market Status | Prescription |
| Company | United Therap |
For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
FDA Label
Treatment of adult patients with WHO Functional Class (FC) III or IV and:
- inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or
- persistent or recurrent CTEPH after surgical treatment
to improve exercise capacity.
Treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
B01AC21
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AC - Platelet aggregation inhibitors excl. heparin
B01AC21 - Treprostinil
Absorption
Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.
Volume of Distribution
14 L/70 kg
Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. There have been no studies that evaluate the potential of treprostinil to induce these enzymes.
Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.
The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.
Market Place
